131.06
Schlusskurs vom Vortag:
$132.31
Offen:
$132.6
24-Stunden-Volumen:
1.65M
Relative Volume:
1.07
Marktkapitalisierung:
$276.85B
Einnahmen:
$53.40B
Nettoeinkommen (Verlust:
$13.68B
KGV:
19.03
EPS:
6.8864
Netto-Cashflow:
$16.89B
1W Leistung:
+0.07%
1M Leistung:
+2.35%
6M Leistung:
+26.20%
1J Leistung:
+13.33%
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
131.06 | 256.13B | 53.40B | 13.68B | 16.89B | 6.8864 |
![]()
LLY
Lilly Eli Co
|
855.35 | 758.15B | 53.26B | 13.80B | -50.20M | 15.08 |
![]()
JNJ
Johnson Johnson
|
191.08 | 456.84B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
230.69 | 408.50B | 58.33B | 3.73B | 18.24B | 2.1013 |
![]()
MRK
Merck Co Inc
|
87.50 | 215.81B | 63.43B | 16.42B | 14.72B | 6.4861 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2025-02-13 | Herabstufung | UBS | Buy → Neutral |
2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
2022-12-05 | Hochstufung | Stifel | Hold → Buy |
2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | Fortgesetzt | Citigroup | Buy |
2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
2021-03-10 | Herabstufung | Argus | Buy → Hold |
2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-09-10 | Hochstufung | UBS | Neutral → Buy |
2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
2019-04-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-12-11 | Fortgesetzt | Jefferies | Buy |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-01-25 | Bestätigt | Leerink Partners | Outperform |
2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Should You Buy Novartis Stock Before October 28? - Barchart.com
Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances - GlobeNewswire Inc.
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
UBS Sticks to Their Hold Rating for Novartis AG (NOVN) - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm
BioArctic and Novartis Sign an Option, Collaboration and License Agreement Using BrainTransporter for an Upfront Payment of USD 30 Million Plus Additional Potential Milestones and Royalties - 富途牛牛
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com
2 Dividend Stocks to Buy and Hold - sharewise.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):